Effect of pravastatin on apolipoproteins B and C-III in very-low-density lipoproteins and low-density lipoproteins.
Sacks
Frank M
FM
Nutrition Department, Harvard School of Public Health, Boston, Massachusetts 02115, USA. fsacks@hsph.harvard.edu
Alaupovic
Petar
P
Moye
Lemuel A
LA
D000924:Anticholesteremic Agents / Q000494:pharmacology; D053305:Apolipoprotein C-III; D001055:Apolipoproteins B / Q000097:blood / Q000187:drug effects*; D001056:Apolipoproteins C / Q000097:blood / Q000187:drug effects*; D003327:Coronary Disease / Q000097:blood / Q000188:drug therapy; D005260:Female; D006801:Humans; D008075:Lipoproteins, HDL / Q000097:blood / Q000187:drug effects; D008077:Lipoproteins, LDL / Q000097:blood / Q000187:drug effects*; D008079:Lipoproteins, VLDL / Q000097:blood / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D017035:Pravastatin / Q000494:pharmacology*; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood
D000924:Anticholesteremic Agents; D053305:Apolipoprotein C-III; D001055:Apolipoproteins B; D001056:Apolipoproteins C; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D014280:Triglycerides; D017035:Pravastatin